ArticleJournal of pain research2025
Carnitine and Other Metabolites in Fibromyalgia a Clinical Perspective on a Mendelian Randomization Study.
Article in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fibromyalgia (FM) is a chronic pain disorder lacking reliable biomarkers. While metabolomic studies have suggested associations with various metabolites, including carnitine, establishing causality remains a challenge. This study integrates clinical metabolomic profiling with a Mendelian Randomization (MR) framework to investigate the potential causal influence of blood metabolites on FM. Methods: In this study, 96 patients with Fibromyalgia and normal controls were recruited, and the carnitine level in peripheral blood was detected by ELISA method. And then, a two-sample Mendelian randomization (MR) method was used to test the potential causal relationship between 1400 metabolite biomarkers, including the level of carnitine, and Fibromyalgia. Additionally, for those metabolites demonstrating a causal link to Fibromyalgia in the initial MR analysis, a reverse Mendelian Randomization analysis was conducted to further validate these findings. Results: Carnitine levels were markedly decreased in patients with fibromyalgia compared with healthy controls. The MR analysis identified 10 metabolites potentially causally linked to fibromyalgia. Among them, carnitine has a causal relationship with Fibromyalgia and is a protective factor (OR 0.73, 95% CI: 0.59-0.91, p = 0.004). There are others, 4 metabolites showed protective effects, whereas 5 were linked to an elevated risk of the condition. The results were consistent among various MR methods, suggesting a strong correlation. Conclusion: Our findings provide novel evidence supporting a potential causal, protective role of carnitine in FM pathogenesis, alongside other implicated metabolites. These results highlight the promise of metabolic pathways as targets for intervention, but future studies in larger, diverse populations are warranted to confirm these relationships.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.